Buy Sanofi India; target of Rs 9820: ICICI Direct
ICICI Direct is bullish on Sanofi India recommended buy rating on the stock with a target price of Rs 9820 in its research report dated February 24, 2021.
February 26, 2021 / 01:02 PM IST
ICICI Direct's research report on Sanofi India
CY20 revenues de-grew 5.5% YoY to Rs 2902 crore mainly due to divestiture of few products to Zentiva (Ankaleshwar slump sale) and Covid-19 impact on certain therapies. EBITDA margins improved 291 bps YoY to 24.6% mainly due to lower other expenditure and slightly better gross margins. Subsequently, EBITDA grew 7.2% YoY to Rs 713 crore. Adjusted PAT grew 9.7% YoY to Rs 519 crore. Note: Results are not comparable YoY due to closure of the Zentiva transaction on May 29, 2020.
We maintain BUY with a target price of Rs 9820 (unchanged) based on 35x CY22E EPS of Rs 280.6.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.